According to recent findings outlined in a clinical trial presented at the American Heart Association Scientific Sessions 2020, polypill, when combined with aspirin, was observed to lower cardiovascular disease (CVD) risk. The novel polypill consists of 100 mg atenolol, 10 mg ramipril, 25 mg hydrochlorothiazide, and 40 mg simvastatin.
The International Polycap Study (TIPS)-3 was conducted in nine countries with a sample size of 5700 subjects suffering from CVD. The participants were randomly allocated to the following interventions along with a matched placebo-controlled arm: 75 mg aspirin daily A polypill daily Polypill plus 75 mg aspirin daily 5,000 IU vitamin D daily Over a follow-up duration of almost five years, patients were checked for the occurrence of major coronary events, such as non-fatal heart attack, non-fatal stroke, heart disease, resuscitated cardiac arrest, and…
